Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 12.18%11.42B | 30.81%3.13B | 2.50%2.68B | 7.07%2.6B | 9.69%3.01B | 13.66%10.18B | 10.15%2.39B | 12.60%2.61B | 13.35%2.43B | 18.30%2.74B |
Cost of revenue | 12.72%8.78B | 36.45%2.48B | 2.72%1.99B | 8.06%2B | 5.78%2.31B | 9.76%7.79B | 5.97%1.82B | 13.22%1.93B | 18.84%1.85B | 3.35%2.19B |
Gross profit | 10.43%2.64B | 12.96%648.1M | 1.90%692.42M | 3.93%605.49M | 24.97%698.84M | 28.53%2.4B | 25.88%573.75M | 10.86%679.49M | -1.14%582.62M | 172.22%559.23M |
Operating expense | 27.23%1.66B | 48.93%497.6M | 25.98%426.47M | 13.70%355.75M | 19.08%377.75M | 6.97%1.3B | 8.84%334.11M | 8.95%338.54M | 9.22%312.9M | 1.13%317.22M |
Operating profit | -9.62%987.28M | -37.20%150.5M | -22.00%265.95M | -7.41%249.74M | 32.68%321.09M | 69.20%1.09B | 61.04%239.64M | 12.83%340.96M | -10.94%269.72M | 323.56%242M |
Net non-operating interest income (expenses) | 4.78%-95.86M | 5.70%-23.38M | 2.89%-23.9M | 4.24%-23.95M | 6.21%-24.64M | 5.84%-100.68M | 6.11%-24.79M | 5.22%-24.61M | 7.41%-25.01M | 4.61%-26.27M |
Non-operating interest income | -24.36%1.09M | -24.94%307K | -25.32%236K | -21.03%308K | -26.71%236K | -1.44%1.44M | 3.81%409K | -3.66%316K | -2.50%390K | -4.17%322K |
Non-operating interest expense | -5.06%96.95M | -6.01%23.69M | -3.18%24.14M | -4.50%24.26M | -6.46%24.87M | -5.78%102.12M | -5.96%25.2M | -5.20%24.93M | -7.34%25.4M | -4.61%26.59M |
Net investment income | 123.55%186.71M | 1,579.32%89M | 112.51%44.64M | -26.06%2.98M | -5.84%50.08M | -17.53%83.52M | 27.10%5.3M | -14.67%21.01M | -39.89%4.03M | -19.16%53.19M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 13.35%-20M | 0 | 0 | -236.89%-23.08M | -91.26%425K | -110.20%-559K | -90K | -22.86M | ||
Income from associates and other participating interests | 151.42%263.01M | 28.53%105.28M | 618.69%63.61M | 56.92%62.48M | 221.89%31.65M | 49.70%104.61M | 8.09%81.91M | 72.70%8.85M | 279.61%39.81M | -20.70%-25.97M |
Special income (charges) | 37.32%15.92M | 0 | 15.03M | -10.63M | -0.61%11.52M | -73.01%11.59M | 0 | 0 | 0 | 1,510.14%11.59M |
Less:Other special charges | -37.32%-15.92M | --0 | ---15.03M | --10.63M | 0.61%-11.52M | 73.01%-11.59M | --0 | --0 | --0 | -1,510.14%-11.59M |
Other non-operating income (expenses) | 1,905.96%64.85M | 34.10%33.81M | -50.75%-26.11M | 414.20%39.64M | 1,451.20%17.51M | -110.29%-3.59M | -11.57%25.22M | -164.81%-17.32M | -242.41%-12.62M | -72.17%1.13M |
Income before tax | 20.37%1.4B | 8.40%355.22M | -2.77%319.22M | 16.10%320.25M | 74.91%407.22M | 44.76%1.16B | 17.13%327.7M | 8.16%328.32M | -10.43%275.85M | 368.45%232.82M |
Income tax | 2.99%395.78M | 73.78%122.33M | -32.63%86.14M | -21.95%73.61M | 23.96%113.7M | 77.05%384.28M | 45.00%70.39M | 35.60%127.86M | 5.32%94.31M | 698.19%91.72M |
Net income | 28.92%1.01B | -9.49%232.89M | 16.27%233.08M | 35.86%246.63M | 108.03%293.53M | 32.84%780.42M | 11.28%257.31M | -4.20%200.47M | -16.89%181.54M | 297.64%141.1M |
Net income continuous operations | 28.92%1.01B | -9.49%232.89M | 16.27%233.08M | 35.86%246.63M | 108.03%293.53M | 32.84%780.42M | 11.28%257.31M | -4.20%200.47M | -16.89%181.54M | 297.63%141.1M |
Noncontrolling interests | 27.97%60.41M | -85.49%1.69M | 2,852.70%41.01M | -102.86%-313K | -22.37%18.02M | -46.30%47.21M | -38.61%11.66M | -92.84%1.39M | -47.51%10.94M | -19.02%23.21M |
Net income attributable to the company | 28.98%945.72M | -5.88%231.2M | -3.52%192.07M | 44.76%246.95M | 133.71%275.51M | 46.76%733.21M | 15.75%245.65M | 4.86%199.08M | -13.65%170.59M | 217.81%117.89M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 28.98%945.72M | -5.88%231.2M | -3.52%192.07M | 44.76%246.95M | 133.71%275.51M | 46.76%733.21M | 15.75%245.65M | 4.86%199.08M | -13.65%170.59M | 217.81%117.89M |
Gross dividend payment | ||||||||||
Basic earnings per share | 29.32%71.76 | -4.90%17.68 | -3.45%14.55 | 44.69%18.68 | 133.74%20.85 | 46.76%55.49 | 15.75%18.59 | 4.87%15.07 | -13.65%12.91 | 217.83%8.92 |
Diluted earnings per share | 29.21%71.7 | -4.99%17.66 | -3.57%14.53 | 44.62%18.67 | 133.63%20.84 | 46.80%55.49 | 15.74%18.5875 | 4.93%15.0681 | -13.65%12.91 | 217.83%8.92 |
Dividend per share | 6.67%16 | 0.00%8 | 0 | 14.29%8 | 0 | 7.14%15 | 14.29%8 | 0 | 0.00%7 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |